After 4 years of research and development by Shandong Hubble Kisen Biological Technology Co., Ltd., a subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd., Aitingjiu (Dapoxetine Hydrochloride Tablets), the first domestic medicine for the treatment of PE “Premature Ejaculation”, was approved by the National Medical Products Administration (NMPA) ), and held an approved online press conference on April 22, 2020.

Chairman of the Andrology Branch of the Chinese Medical Association, Professor Deng Chunhua, Director of the Andrology Department of the First Affiliated Hospital of Sun Yat-sen University, Chief Editor of "Chinese Journal of Andrology", Dr. Zhang Yadong, the First Affiliated Hospital of Sun Yat-sen University, and Professor Shang Xuejun, the director-designate of the Andrology Branch of the Chinese Medical Association, etc. Several authoritative experts in andrology were invited to attend the meeting. From a professional and authoritative perspective, they analyzed the positive impact of the approval of Aitingjiu on the treatment of male premature ejaculation, the acquisition of clinical diagnosis and treatment data, and the development of andrology health.

As the first domestically produced drug for the treatment of premature ejaculation, Aitingjiu has broken the monopoly of foreign-funded enterprises in China’s premature ejaculation drug market. By reducing treatment costs, it will help improve the chances of patients receiving effective treatment and help respond to the different needs of premature ejaculation patients.

In the future, relying on the brand advantages and channel advantages of Taienkang, supplemented by the quality and technology advantages of Aitingjiu and the advantages of cost performance, it is believed that in the near future, Aitingjiu will become the first choice brand for the treatment of premature ejaculation in China, bringing consumers We have more surprises!